103 related articles for article (PubMed ID: 16841374)
1. Putting the colours into chromogenic in situ hybridization (CISH).
Shipley J
J Pathol; 2006 Sep; 210(1):1-2. PubMed ID: 16841374
[TBL] [Abstract][Full Text] [Related]
2. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.
Laakso M; Tanner M; Isola J
J Pathol; 2006 Sep; 210(1):3-9. PubMed ID: 16823892
[TBL] [Abstract][Full Text] [Related]
3. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
Pedersen M; Rasmussen BB
Diagn Mol Pathol; 2009 Jun; 18(2):96-102. PubMed ID: 19430295
[TBL] [Abstract][Full Text] [Related]
4. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Francis GD; Jones MA; Beadle GF; Stein SR
Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
[TBL] [Abstract][Full Text] [Related]
5. Chromogenic in situ hybridization in tumor pathology.
Isola J; Tanner M
Methods Mol Med; 2004; 97():133-44. PubMed ID: 15064490
[No Abstract] [Full Text] [Related]
6. HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization.
Ntoulia M; Kaklamanis L; Valavanis C; Kafousi M; Stathopoulos E; Arapantoni P; Mavroudis D; Georgoulias V; Lianidou ES
Clin Biochem; 2006 Sep; 39(9):942-6. PubMed ID: 16916505
[TBL] [Abstract][Full Text] [Related]
7. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.
Yan B; Choo SN; Mulyadi P; Srivastava S; Ong CW; Yong KJ; Putti T; Salto-Tellez M; Lim GS
J Clin Pathol; 2011 Dec; 64(12):1097-101. PubMed ID: 21896578
[TBL] [Abstract][Full Text] [Related]
8. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens.
García-Caballero T; Grabau D; Green AR; Gregory J; Schad A; Kohlwes E; Ellis IO; Watts S; Mollerup J
Histopathology; 2010 Mar; 56(4):472-80. PubMed ID: 20459554
[TBL] [Abstract][Full Text] [Related]
9. Detection of c-myc amplification in formalin-fixed paraffin-embedded tumor tissue by chromogenic in situ hybridization (CISH).
Todorović-Raković N
Methods Mol Biol; 2013; 1012():249-54. PubMed ID: 24006070
[TBL] [Abstract][Full Text] [Related]
10. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
[TBL] [Abstract][Full Text] [Related]
11. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.
Di Palma S; Collins N; Bilous M; Sapino A; Mottolese M; Kapranos N; Schmitt F; Isola J
J Clin Pathol; 2008 Jun; 61(6):757-60. PubMed ID: 18326010
[TBL] [Abstract][Full Text] [Related]
12. Chromogenic In Situ Hybridization (CISH) as a Method for Detection of C-Myc Amplification in Formalin-Fixed Paraffin-Embedded Tumor Tissue: An Update.
Todorović-Raković N
Methods Mol Biol; 2021; 2318():313-320. PubMed ID: 34019299
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dual-colour chromogenic in-situ hybridization and fluorescence in-situ hybridization in the assessment of HER2 gene amplification in breast carcinoma.
Conlon S; Colgan A; Allen D; O'Grady A; Kay EW
Histopathology; 2011 Jan; 58(2):319-21. PubMed ID: 21323957
[No Abstract] [Full Text] [Related]
15. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
[TBL] [Abstract][Full Text] [Related]
16. Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH).
Fischer I; de la Cruz C; Rivera AL; Aldape K
Diagn Mol Pathol; 2008 Dec; 17(4):227-30. PubMed ID: 18382350
[TBL] [Abstract][Full Text] [Related]
17. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.
Gong Y; Sweet W; Duh YJ; Greenfield L; Fang Y; Zhao J; Tarco E; Symmans WF; Isola J; Sneige N
Am J Clin Pathol; 2009 Apr; 131(4):490-7. PubMed ID: 19289584
[TBL] [Abstract][Full Text] [Related]
18. The genomic profile of HER2-amplified breast cancers: the influence of ER status.
Marchiò C; Natrajan R; Shiu KK; Lambros MB; Rodriguez-Pinilla SM; Tan DS; Lord CJ; Hungermann D; Fenwick K; Tamber N; Mackay A; Palacios J; Sapino A; Buerger H; Ashworth A; Reis-Filho JS
J Pathol; 2008 Dec; 216(4):399-407. PubMed ID: 18810758
[TBL] [Abstract][Full Text] [Related]
19. Tissue subtraction DNA in situ hybridization (TSDISH): in situ detection of DNA abnormalities in formalin-fixed paraffin-embedded tissue sections by subtraction hybridization with whole genomic DNA.
Itakura Y; Sasano H; Mori S; Nagura H; Shimizu S
Anticancer Res; 1997; 17(1A):121-8. PubMed ID: 9066641
[TBL] [Abstract][Full Text] [Related]
20. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
